EINSTEIN PE RIVAROXABAN PDF

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AW. Published in , EINSTEIN-PE randomized 4, patients with acute PE to rivaroxaban or standard therapy with enoxaparin and a VKA. Oral, direct Factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis or pulmonary embolism ().

Author: Shakagis Gardarisar
Country: Denmark
Language: English (Spanish)
Genre: Life
Published (Last): 6 June 2017
Pages: 24
PDF File Size: 4.12 Mb
ePub File Size: 18.52 Mb
ISBN: 330-4-24845-303-1
Downloads: 53937
Price: Free* [*Free Regsitration Required]
Uploader: Tygorn

The bleeding rates were similar in the two study groups, with fewer major bleeding events in the rivaroxaban group Close this section.

Usable articles Hematology Pulmonology. The primary efficacy outcome was symptomatic recurrent venous thromboembolism.

EINSTEIN-PE

Recommend page Back to top. In a randomized, open-label, event-driven, noninferiority trial involving patients who had acute symptomatic pulmonary embolism with or without deep-vein thrombosis, we compared rivaroxaban 15 mg twice daily for 3 weeks, followed by 20 mg once daily with rivroxaban therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months.

N Engl J Med ; In addition, its open-label design may have biased both patients rivaroxabxn investigators. The bleeding rates were similar in the two einshein groups, with fewer major bleeding events in the rivaroxaban group.

Major bleeding occured in 1. Among patients with acute PE, is rivaroxaban noninferior to warfarin in preventing recurrent VTE or bleeding? A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein thrombosis, without the need for laboratory monitoring.

  CARCASSONNE INNS AND CATHEDRALS RULES PDF

This approach may also simplify the treatment of pulmonary embolism.

EINSTEIN-PE – Wiki Journal Club

It differed from these studies in several notable ways, however. The principal safety outcome occurred in Rev Clin Esp Barc.

For example, the study’s noninferiority design may have rendered it unable to detect small differences in relative efficacy between treatment arms. Views Read View source View history. N Engl J Med. ESC Guidelines on the diagnosis and management of acute pulmonary embolismadapted: Rates of other adverse events were similar in the two groups. Despite these limitations, there remains a reasonably strong evidence base for rivaroxaban in acute VTE, which led to the Rivaroxsban approval of rivaroxaban for these indications in November The trial’s generalizability is limited for several reasons, including the fact that 1 patients were younger mean age 58 years than the general acute PE population and 2 the trial excluded patients with cancer.

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

Some of these characteristics contribute to the study’s limitations. The principal safety outcome was major or clinically relevant nonmajor bleeding.

At rivarixaban mean follow-up of 7 months, rivaroxaban was noninferior to standard therapy in terms of the rate of recurrent symptomatic VTE 2.

Randomized, open-label phase III non-inferiority study Active treatment: Rivaroxaban was noninferior to standard therapy noninferiority margin, 2. A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of pulmonary embolism and had a potentially improved benefit-risk profile.

It was also one of the first to employ an open-label design lacking matching placebos between groups. To compensate for this, the study used a higher dose during the first 3 weeks of therapy 15mg BID followed rivaroxaan a lower maintenance dose 20mg eisntein.

  HEINER MULLER QUARTET PDF

The outcome of a net clinical benefit occurred in 83 patients 3. Among patients with acute PE, rivaroxaban is noninferior to warfarin in preventing recurrent VTE, and is associated with similar bleeding rates. Comparisons are rivaroxaban vs. Navigation menu Personal tools Create account Log in.

The primary safety endpoint, a first major and clinically relevant non-major bleeding episode, was observed in Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. P values are for noninferiority unless otherwise specified.

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

Oral, direct Factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis or pulmonary embolism Major bleeding was observed in 26 patients 1.

Retrieved from ” http: Comment in N Engl J Med. This page le last modified on 3 Decemberat The New England Journal of Medicine. To compare rivaroxaban to standard anticoagulant therapy with enoxaparin and vitamin K antagonist VKA in the treatment of patients with acute symptomatic PE.

The fixed dose regimen of rivaroxaban is at least as effective for the initial and long-term treatment of PE as the standard therapy with enoxaparin followed by a VKA Safety: Like the others, it employed a noninferiority rather than a superiority design, and enrolled a relatively heterogeneous patient population.